Reith, Christina

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 2,479

Interpretation of the evidence for the efficacy and safety of statin therapy

Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet

Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular Diseases

Cited by 1,857

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 801

Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials

Scally, B., Emberson, J. R., Spata, E., Reith, C., Davies, K., Halls, H., Holland, L., Wilson, K., Bhala, N., Hawkey, C., et al. (2018) · The Lancet Gastroenterology & Hepatology

Helicobacter pylori-related gastroenterology studiesGastrointestinal Bleeding Diagnosis and Treatment

Cited by 259

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors

Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 75

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

Staplin, N., Roddick, A. J., Emberson, J., Reith, C., Riding, A., Wonnacott, A., Kuverji, A., Bhandari, S., Baigent, C., Haynes, R., et al. (2021) · eClinicalMedicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 74

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection

on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 16